These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 25757188

  • 1. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.
    Lähelmä S, Sairanen U, Haikarainen J, Korhonen J, Vahteristo M, Fuhr R, Kirjavainen M.
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):462-73. PubMed ID: 25757188
    [Abstract] [Full Text] [Related]

  • 2. Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma.
    Lähelmä S, Vahteristo M, Metev H, Taseva M, Stamatova N, Bartha A, Schlezák J, Sairanen U.
    Respir Med; 2016 Nov; 120():31-35. PubMed ID: 27817813
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
    Kerwin EM, Siler TM, Arora S, Darken P, Rose E, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov; 13():1483-1494. PubMed ID: 29773947
    [Abstract] [Full Text] [Related]

  • 4. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers.
    Weisfeld L, Shu Y, Shah TP.
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).
    Malmberg LP, Everard ML, Haikarainen J, Lähelmä S.
    J Aerosol Med Pulm Drug Deliv; 2014 Oct; 27(5):329-40. PubMed ID: 24978441
    [Abstract] [Full Text] [Related]

  • 6. A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler®.
    Syk J, Vinge I, Sörberg M, Vahteristo M, Rytilä P.
    Adv Ther; 2019 Jul; 36(7):1756-1769. PubMed ID: 30941722
    [Abstract] [Full Text] [Related]

  • 7. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler.
    Gillen M, Forte P, Svensson JO, Lamarca R, Burke J, Rask K, Larsdotter Nilsson U, Eckerwall G.
    Pulm Pharmacol Ther; 2018 Oct; 52():7-17. PubMed ID: 30077809
    [Abstract] [Full Text] [Related]

  • 8. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
    Lähelmä S, Kirjavainen M, Kela M, Herttuainen J, Vahteristo M, Silvasti M, Ranki-Pesonen M.
    Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.
    Price DB, Thomas V, Richard Dekhuijzen PN, Bosnic-Anticevich S, Roche N, Lavorini F, Raju P, Freeman D, Nicholls C, Small IR, Sims E, Safioti G, Canvin J, Chrystyn H.
    BMC Pulm Med; 2018 Jun 28; 18(1):107. PubMed ID: 29954359
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT, Tashkin DP, Skärby T, Jorup C, Sandin K, Greenwood M, Pemberton K, Trudo F.
    Respir Med; 2017 Nov 28; 132():31-41. PubMed ID: 29229103
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma.
    Virchow JC, Rodriguez-Roisin R, Papi A, Shah TP, Gopalan G.
    BMC Pulm Med; 2016 Mar 17; 16():42. PubMed ID: 26987997
    [Abstract] [Full Text] [Related]

  • 18. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
    Farkas Á, Jókay Á, Balásházy I, Füri P, Müller V, Tomisa G, Horváth A.
    Eur J Pharm Sci; 2016 Oct 10; 93():371-9. PubMed ID: 27552906
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
    Kosoglou T, Hubbell J, Kantesaria B, Hanson ME, Cutler DL.
    Clin Pharmacol Drug Dev; 2014 May 10; 3(3):229-34. PubMed ID: 27128613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.